×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
返回 Agenda
Session 2: The Pitfalls and Promises of Real World Evidence in Evolving the Biosimilar Industry
Session Chair(s)
Mark Stewart, PhD
Vice President, Science Policy
Friends of Cancer Research, United States
Anna Welch, MA
Chief Editor, Biosimilar Development
Life Science Connect, United States
Learning Objective : At the conclusion of this session, participants should be able to:- Evaluate current best-practices and challenges in RWE collection, analysis, and promotion
- Assess evolving strategies for employing RWE in education
- Discuss the impact RWE can have on pre-approval clinical data and the treatment pathway
Speaker(s)
Speaker
Jaclyn Bosco, PhD, MPH, FISPE
IQVIA, United States
Vice President, Global Head of Epidemiology & Database Studies
Speaker
Nancy Lin, DrSc, MS
Optum, United States
Senior Scientist, Epidemiology
Speakers
Edward Li, PharmD, MPH
Sandoz, United States
Associate Director, HEOR & RWE
Speaker
Gianluca Trifiro, MD, PhD
University of Verona, Italy
Scientific Lead, INSPIRE; Professor, Pharmacology, Diagnostics and Public Health